Yes, cilostazol can be used alongside many antihypertensive agents, but dose adjustments may be needed if the patient is also on drugs that affect heart rate or vascular tone. Monitoring blood pressure and heart rate after starting combination therapy is advisable.
A persistent or severe headache may indicate elevated blood pressure or a side effect of cilostazol. Record the intensity and duration, and contact your healthcare provider to determine whether the dose should be adjusted or if an alternative therapy is warranted.
Pletal is a prescription-only medicine (POM) in the UK. When traveling, carry the original prescription label and a copy of the doctor’s note. Some countries may require additional documentation; check the destination’s medication import regulations before departure.
In the UK, the 50 mg tablet is typically white and round, while the 100 mg tablet is often a pink, oval-shaped tablet. Imprint codes may vary by manufacturer batch; consult the packaging for exact identification.
Cilostazol is not commonly screened for in standard workplace drug testing panels. However, if a specialized cardiovascular medication test is ordered, it could be detected. Inform the testing laboratory if you are taking prescription medication.
Aspirin irreversibly inhibits platelet cyclo-oxygenase, reducing thromboxane A₂ production. Cilostazol, by contrast, elevates cAMP to inhibit platelet aggregation while also causing vasodilation. This dual action makes cilostazol more suitable for improving limb blood flow in PAD, whereas aspirin is primarily used for general cardiovascular protection.
Regular, supervised walking programmes, smoking cessation, and a balanced diet rich in omega-3 fatty acids can synergise with cilostazol to improve peripheral circulation. Avoiding heavy meals and excessive alcohol may also reduce the likelihood of dizziness.
Cilostazol can cause bronchospasm in susceptible individuals, although this is rare. Patients with a history of asthma should discuss potential risks with their clinician before starting therapy.
Bathrooms often experience high humidity and temperature fluctuations, which can degrade medication. It is best to store Pletal in a cool, dry place such as a bedroom drawer or a dedicated medication box.
There is no robust evidence that cilostazol interferes with the immune response to vaccines. Patients should receive routine vaccinations as recommended, but should inform the vaccinating clinician of all current medications.
Pletal is a prescription medication that contains the active ingredient cilostazol. It belongs to the cardiovascular therapeutic class and is formulated as a pill. In the United Kingdom, Pletal is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is marketed by Bayer Pharmaceuticals Ltd. The product is available in two strengths: 50 mg and 100 mg tablets. Cilostazol is most commonly prescribed to improve walking distance in people with intermittent claudication due to peripheral arterial disease (PAD).
Cilostazol exerts its effects primarily by inhibiting phosphodiesterase-3 (PDE-3). This inhibition raises intracellular cyclic adenosine-monophosphate (cAMP) levels in vascular smooth-muscle cells and platelets. The resulting actions are twofold:
These mechanisms together help relieve the muscle pain and fatigue that occur during walking in PAD patients. The onset of action typically appears within a few days, with maximal therapeutic benefit emerging after several weeks of consistent dosing.
In the UK, Pletal is approved for the symptomatic treatment of intermittent claudication in adults with peripheral arterial disease. The medication is intended to increase walking distance and improve quality of life for patients whose blood flow to the lower limbs is compromised by atherosclerotic narrowing. It is not indicated for the treatment of coronary artery disease, stroke prevention, or general hypertension.
Cilostazol has been investigated for several indications beyond intermittent claudication, including:
Because these uses are not approved by the MHRA, any off-label prescribing must be undertaken by a qualified clinician after a thorough risk-benefit assessment.
Patients should report persistent or worsening symptoms to their healthcare professional.
Any signs of significant bleeding (e.g., unusual bruising, haematemesis) or respiratory distress require immediate medical attention.
This article provides educational information about Pletal and is not a substitute for professional medical advice. Treatment decisions, including the use of medications for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
